94, 95% Cl: 1.7727.03, p=0.005] or not was only associated with bleeding after prophylactic EVL. Conclusions: No administration of PPI was significantly associated with increased risk of bleeding after prophylactic EVL. Especially, PPI medication was the only predictor factor in the case of no gastric varix. We suggest PPI therapy should be routinely performed in patients receiving EVL to reduce the risk of post EVL bleeding. Disclosures: Hyung Joon Yim – Grant/Research Support: GSK Korea, Handok Pharm, Gilead

Korea; Speaking and Teaching: BMS Korea The following people have nothing to disclose: Seong Hee Kang, Seung Young Kim, Hae Rim Kim, Eileen L. Yoon, Hyun Jung Lee, Sang Jun Suh, Sung Woo Jung, Ja Seol Koo, Ji Hoon Kim, Yeon Seok Seo, Rok Son Choung, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um, Sang Woo Lee, Jai Hyun Choi, Ho Sang Ryu Background and Aims Transjugular intrahepatic portosystemic ABT 737 shunt (TIPS) is a common and effective treatment of refractory ascites or refractory variceal bleeding in patients with portal hypertension and cirrhosis. It is unclear whether TIPS has any long-term effects on patient survival in patients with cirrhosis. We aimed to determine whether TIPS is associated with survival in patients with cirrhosis. Methods We created a cohort of adult patients with cirrhosis without previous liver transplantation who were listed for liver transplantation in the United States between 2002-2011

(n=80,519) and followed from the time of listing until the time of death on the waiting list, CX-5461 cell line transplantation, or drop-out from the waiting list. Patients Phospholipase D1 were censored if they were still on the waiting list at the time of last follow-up. We used Cox proportional hazards analysis and competing risks analysis to compare patients who had TIPS at the time of listing

(n=6115) to those who did not (n=74,044) with regards to death on the waiting list, transplantation and drop-out from the waiting list, after adjusting for important baseline characteristics (MELD score, underlying liver disease, presence of hepatocellular carcinoma, age, gender, race/ethnicity, diabetes, body mass index, serum albumin, ascites, encephalopathy, portal vein thrombosis, and ABO blood group) Results Among 80, 519 patients listed for liver transplantation, 10, 920 (14%) died on the waiting list, 40,180 (50%) underwent transplantation, 11,288 (14%) dropped out, and 17,771 (22%) were still on the waiting list during a mean follow-up of 1.2 years. Compared to patients who did not have a TIPS, those with a TIPS had lower risk of death on the waiting list (adjusted hazard ratio [AHR] 0.83 95% Cl 0.78-0.90). They also had a lower likelihood of transplantation (AHR 0.87 [0.83-0.90]) and dropout from the waiting list (AHR 0.92 [0.86-0.99]) suggesting that the lower risk of death could not be explained by higher rate of removal of relatively sick patients from the waiting list due to transplantation or drop-out.